# US 6,730,684 B1 · Fab I inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,684 B1
- Document ID: US6730684B1
- Status: Granted
- Kind: B1
- Application number: 10/089,740
- Filed: 2002-04-03
- Granted: 2004-05-04
- Earliest claimed: 1999-10-08
- Assignees: Affinium Pharmaceuticals, Inc.
- Inventors: William H. Miller; Kenneth A. Newlander; Mark A. Seefeld; Irene N. Uzinskas
- Web page: https://patentgrep.com/patent/US6730684B1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.

## Claims

### Claim 1

A compound according to formula (I) or (II):
wherein:
R1 is H or C1-4alkyl;
R2 is C1-4alkyl;
R3 is
Q is a single bond, —O—, —S—, —NH—, —CH2—, or —CH2CH2—;
R4 is C1-6alkyl, OC1-6alkyl, OH, CF3 or piperidinyl;
is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R5;
is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R6;
is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R6;
R5 is OR′ or NR′C(O)R′;
R6 is OR′ or N(R′)2;
X is H, C1-4alkyl, OR′, SR′, CN, N(R′)2, CH2N(R′)2, NO2, CF3, CO2R′, CON(R′)2, COR′, NR′C(O)R′, F, Cl, Br, I or —S(O)rCF3;
R′ is H, C1-6alkyl or —C0-6alkyl-Ar; and
r is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 of formula (Ia):

### Claim 3 (depends on 1)

A compound according to claim 1 in which R3 is:

### Claim 4 (depends on 3)

A compound according to claim 3 in which
is 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thiophenyl, thiazolyl, phenyl or phenyl substituted by OC1-4alkyl or NHC(O)C1-4alkyl.

### Claim 5 (depends on 4)

A compound according to claim 4 in which
is 3- or 4-pyridyl, 3-furanyl, 3-thiophenyl, phenyl or phenyl substituted by OCH3 or NHC(O)CH3.

### Claim 6 (depends on 3)

A compound according to claim 3 in which
is 2-, 3- or 4-pyridyl, phenyl or phenyl substituted by OH or NH2.

### Claim 7 (depends on 6)

A compound according to claim 6 in which
is phenyl or 2-pyridyl.

### Claim 8 (depends on 3)

A compound according to claim 3 in which Q is a single bond.

### Claim 9 (depends on 3)

A compound according to claim 3 in which Q is —O— or —CH2—.

### Claim 10 (depends on 1)

A compound according to claim 1 in which R3 is:

### Claim 11 (depends on 10)

A compound according to claim 10 in which
is phenyl unsubstituted or substituted by OH, NH2 or N(CH3)2 and R4 is C1-4alkyl, OC1-4alkyl, OH, CF3, or piperidinyl.

### Claim 12 (depends on 1)

A compound according to claim 1 of formula (IIa):

### Claim 13 (depends on 1)

A compound according to claim 1 which is:
2-[2-(4-Methoxyphenyl)ethyl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]nicotinamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-phenylbenzamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(pyridin-4-yl)benzamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(pyridin-3-yl)benzamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(thiophen-3-yl)benzamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(furan-3-yl)benzamide;
N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-phenoxybenzamide;
N,2-Dimethyl-N-[(1-methyl-1H-indol-2-yl)methyl]benzamide;
2-[3-(Acetylamino)phenyl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]benzamide;
2-methoxy-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)benzamide;
2,4-dihydroxy-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)benzamide;
2-dimethylamino-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)benzamide;
N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-2-(piperidin-1-yl)benzamide;
N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-2-(trifluoromethyl)benzamide;
4-amino-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-2-phenoxybenzamide;
N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-2-phenoxynicotinamide;
N-methyl-N-(1-methyl-1H-indazol-3-ylmethyl)-2-phenylbenzamide;
N-methyl-N-(1-methyl-1H-indazol-3-ylmethyl)-2-phenoxybenzamide;
2-[3-(acetylamino)phenoxy]-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-benzamide;
2-[3-(acetylamino)phenyl]-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-benzamide; or
2-[3-(acetylamino)phenyl]-5-amino-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)benzamide;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method for inhibiting FabI which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 16 (depends on 1)

A method of treating bacterial infections which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 17 (depends on 1)

A process for preparing compounds of formula (I) or (II) as defined in claim 1, which process comprises:
(i) reacting a compound of formula (III) with a compound of formula (IV):
wherein R1, R2, R3 and X are as defined in formula (I), with any reactive functional groups protected, in the presence of EDC and HOBT; or
(ii) reacting a compound of formula (V) with a compound of formula (IV):
wherein R1, R2, R3 and X are as defined in formula (I), with any reactive functional groups protected, in the presence of EDC and HOBT;
and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.
